Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis

Clinical Cancer Research

Volumn 18, Issue 16, 2012, Pages 4334-4344

  Tone, Alicia A ^a,b,c,d   Virtanen, Carl ^c   Shaw, Patricia ^b,c   Brown, Theodore J ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER SUSCEPTIBILITY; DAB2 GENE; EPITHELIUM; FOLLICULAR PHASE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HIGH GRADE SEROUS CARCINOMA; HUMAN; INFLAMMATION; LUTEAL PHASE; NUCLEOTIDE SEQUENCE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RNA EXTRACTION; SIGNAL TRANSDUCTION; SOD2 GENE; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE; UTERINE TUBE MUCOSA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BRCA1 PROTEIN; CELL LINE; CLUSTER ANALYSIS; DEXAMETHASONE; EPITHELIUM; FALLOPIAN TUBES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; NF-KAPPA B; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865088153     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0199     Document Type: Article

References (54)

1. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011;121:353-7.
2. Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res 2008;14:4067-78.
3. Tone AA, Virtanen C, Shaw PA, Brown TJ. Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma. Endocr Relat Cancer 2011;18:221-34.
4. Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 2006;247:4-21.
5. Revelli A, Delle Piane L, Casano S, Molinari E, Massobrio M, Rinaudo P. Follicular fluid content and oocyte quality: from single biochemical markers to metabolomics. Reprod Biol Endocrinol 2009;7:40.
6. Johnson ML, Murdoch J, Van Kirk EA, Kaltenbach JE, Murdoch WJ. Tumor necrosis factor alpha regulates collagenolytic activity in preovulatory ovine follicles: relationship to cytokine secretion by the oocyte-cumulus cell complex. Biol Reprod 1999;61:1581-5.
7. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-33.
8. Amsterdam A, Sasson R. The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol Cell Endocrinol 2002;189:1-9.
9. Murdoch WJ, Martinchick JF. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood) 2004;229:546-52.
10. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-76.
11. Ma Y, Katiyar P, Jones LP, Fan S, Zhang Y, Furth PA, et al. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol 2006;20:14-34.
12. Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A 2001;98:9587-92.
13. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 2000;60:5946-9.
14. Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res 2005;65:9906-13.
15. Tseng CP, Ely BD, Pong RC, Wang Z, Zhou J, Hsieh JT. The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer. J Biol Chem 1999;274:31981-6.
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
17. Kollara A, Brown TJ. Functional interaction of nuclear receptor coactivator 4 with aryl hydrocarbon receptor. Biochem Biophys Res Commun 2006;346:526-34.
18. Rae MT, Hillier SG. Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab 2005;16:327-33.
19. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal fallopian tube: anew model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9.
20. Karlan B, Boyd J, Strong L, Garber J, Fountain J, Beller U. Discussion: hereditary ovarian cancer. Gynecol Oncol 2003;88:S11-3.
21. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
22. George SH, Greenaway J, Milea A, Clary V, Shaw S, Sharma M, et al. Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers. J Pathol 2011;225:106-17.
23. McGuire V, Felberg A, Mills M, Ostrow KL, DiCioccio R, John EM, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 2004;160:613-8.
24. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007;8:26-34.
25. Tung KH, Wilkens LR, Wu AH, McDuffie K, Nomura AM, Kolonel LN, et al. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol 2005;161:321-9.
26. Saleemuddin A, Folkins AK, Garrett L, Garber J, Muto MG, Crum CP, et al. Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Gynecol Oncol 2008;111:226-32.
27. Vicus D, Shaw PA, Finch A, Rosen B, Murphy J, Armel S, et al. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers. Gynecol Oncol 2010;118:295-8.
28. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 2008;98:1781-3.
29. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010;2010:932371.
30. King SM, Hilliard TS, Wu LY, Jaffe RC, Fazleabas AT, Burdette JE. The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer. Endocr Relat Cancer 2011;18:627-42.
31. Salvador S, Gilks B, Kobel M, Huntsman D, Rosen B, Miller D. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 2009;19:58-64.
32. Vercellini P, Crosignani P, Somigliana E, Vigano P, Buggio L, Bolis G, et al. The 'incessant menstruation' hypothesis: a mechanistic ovarian cancer model with implications for prevention. Hum Reprod 2011;26:2262-73.
33. Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, et al. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep 2009;22:233-40.
34. Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC, et al. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 1994;52:247-52.
35. Anupam K, Tusharkant C, Gupta SD, Ranju R. Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J Gastroenterol 2006;12:6041-5.
36. Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, Howe PH. Regulation of the Wnt signaling pathway by disabled-2 (Dab2).EMBO J 2003;22:3084-94.
37. Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O'Brien DI, et al. Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest 2010;120:2842-57.
38. Hocevar BA, Smine A, Xu XX, Howe PH. The adaptor molecule disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J 2001;20:2789-801.
39. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003;24:488-522.
40. Karihtala P, Soini Y, Vaskivuo L, Bloigu R, Puistola U. DNA adduct 8- hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma. Int J Gynecol Cancer 2009;19:1047-51.
41. Pani G, Bedogni B, Anzevino R, Colavitti R, Palazzotti B, Borrello S, et al. Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells. Cancer Res 2000;60:4654-60.
42. Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, et al. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 2004;64:7893-909.
43. Dziaman T, Huzarski T, Gackowski D, Rozalski R, Siomek A, Szpila A, et al. Elevated level of 8-oxo-7,8-dihydro-2′-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls. Int J Cancer 2009;125:2209-13.
44. Palter SF, Mulayim N, Senturk L, Arici A. Interleukin-8 in the human fallopian tube. J Clin Endocrinol Metab 2001;86:2660-7.
45. Wollen AL, Sandvei R, Mork S, Marandon JL, Matre R. In situ characterization of leukocytes in the fallopian tube inwomen with or without an intrauterine contraceptive device. Acta Obstet Gynecol Scand 1994;73:103-12.
46. Gaytan M, Morales C, Bellido C, Sanchez-Criado JE, Gaytan F. Macrophages in human fallopian tube and ovarian epithelial inclusion cysts. J Reprod Immunol 2007;73:66-73.
47. Jin HS, Lee DH, Kim DH, Chung JH, Lee SJ, Lee TH. cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation. Cancer Res 2009;69:1782-91.
48. Lakshminarayanan V, Drab-Weiss EA, Roebuck KA. H2O2 and tumor necrosis factor-alpha induce differential binding of the redox-responsive transcription factors AP-1 and NF-kappaB to the interleukin-8 promoter in endothelial and epithelial cells. J Biol Chem 1998;273:32670-8.
49. Webster JC, Huber RM, Hanson RL, Collier PM, Haws TF, Mills JK, et al. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology 2002;143:3866-74.
50. Benezra M, Chevallier N, Morrison DJ, MacLachlan TK, El-Deiry WS, Licht JD. BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J Biol Chem 2003;278:26333-41.
51. Greer JB, Whitcomb DC. Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut 2007;56:601-5.
52. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007;96:11-5.
53. Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol 2002;10:153-69.
54. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 2010;11:1133-46.